ClinicalTrials.gg
RecruitingNCT06323889LIMITFOOD2Updated Dec 20, 2024

Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults

An interventional study of Modified Alternate Day Fasting and Time-Restricted Eating in Intermittent Fasting, Obesity and Time Restricted Eating, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.

Read the detailed description

The prevalence of overweight and obesity worldwide has risen considerably in the past century with more than one billion overweight persons, and about 600 million obese patients in 2015. Humans in modern societies typically eat at least three main meals per day and snacks around the clock. This change in eating pattern in terms of quantity and frequency leads to overconsumption of food and consequently to excess weight. Furthermore, obesity increases the risk of developing diabetes, cardiovascular disease and several types of cancer. The world health organization (WHO) has stated that there are 2.8 million deaths per year as a result of overweight and obesity.

In recent years, the concept of re-introduced fasting intervals in the form of intermittent fasting (IF) protocols became a popular alternative dietary strategy with the aim to achieve weight control and improve metabolic health. There are several different IF protocols, the most popular is time-restricted eating (TRE), which allows ad libitum (at one's pleasure) energy intake within a defined time period each time (6 to 12 hours). Another IF protocol is alternate day fasting (ADF), on 'feast days' one can consume food ad libitum, while on 'fast days' no or little food is consumed, feast and fast days alternate throughout the week. Animal studies and previous human clinical trials have provided evidence that various types of IF lead to weight loss and improved health markers. So far, interventional studies focused on the comparison of IF versus a control group, however only few studies compared different IF protocols directly. Given both the evidence for beneficial effects of IF as well as its growing popularity, it seems mandatory to reveal possible differences in the effectiveness of different protocols.

The present project will allow to directly compare two types of IF with each other and with a control group in obese participants. Furthermore, established and novel monitoring tools to track individual progress during IF are scarcely used so far but may become an important help in the future and thus, will be implemented in this trial.

02

Conditions studied

  • Intermittent Fasting
  • Obesity
  • Time Restricted Eating

Keywords

  • Overnutrition
  • Nutrition Disorders
  • Body Weight
  • Obesity
  • Longitudinal monitoring
03

In context

Intermittent Fasting

334 studies on the registry are indexed under Intermittent Fasting; 100 are open to participants now.

This study's planned enrollment of 90 is above the median of 50 across 321 interventional studies indexed under Intermittent Fasting.

Browse Intermittent Fasting studies →

Lead sponsor

University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-50 years, both inclusive
  • Obese, between 30 and 40 kg/m\^2 (obesity grade I or II), both inclusive
  • Non-smoker
  • Good knowledge of German or English language
  • Stable weight change (change \< +/- 3% current bodyweight) for 3 months prior to the study
  • \< 6.5% without glucose lowering medication
  • LDL-cholesterol \< 4.6mmol/l without lipid lowering medication

Exclusion criteria

Exclusion Criteria:

  • Participants who have a fasting period of > 12h per day on a regular basis and do not eat at least three main meals per day.
  • Current habitual use of dietary supplements (e.g., vitamins, minerals) and/or unwillingness to cease intake of dietary supplements.
  • Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters
  • Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle)
  • Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study.
  • Diabetes
  • Known alcohol, substance or drug abuse, concomitant medication
  • More than four hours of physical exercise per week
  • Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial
  • Women and men on hormonal supplementation
  • Women with an irregular menstrual cycle according to the FIGO criteria
  • Therapy with antidepressants within the past 6 months
  • Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids
  • Participants likely to fail to comply with the study protocol
  • Participants who do not give
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Modified Alternate Day Fasting (mADF)

    Participants in the mADF group will be instructed to eat every second-day ad libitum ("feast days"), and to consume a very low carbohydrate snack, restricted to the evening, provided by the study team and to otherwise abstain from calorie intake on the rest of the fast day.

    Behavioral: Modified Alternate Day Fasting

  • Active comparator
    Time-Restricted Eating (TRE)

    TRE participants are instructed to eat two main meals and limit snacking from 12:00 to 20:00 daily, and to fast from 20:00 until 12:00 daily

    Behavioral: Time-Restricted Eating

  • Other
    Control group

    The control group will receive guidance on a quantitative reduction in total caloric intake by following a balanced diet, but no timing window for food intake will be prescribed to the participants in the control group.

    Behavioral: Weight-loss counseling

Interventions

  • BehavioralModified Alternate Day Fasting

    Participants are instructed to fast every other day.

  • BehavioralTime-Restricted Eating

    Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day

  • BehavioralWeight-loss counseling

    Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.

06

What researchers measure

Primary outcomes

  1. Fat Volume

    Change in body fat volume measured with MRI

    Time frame: 8 weeks

Secondary outcomes

  1. Distribution of fat volume

    Changes in subcutaneous and visceral fat volume measured with MRI

    Time frame: 8 weeks

  2. Concentration of Leptin

    Change in leptin concentrations will be measured.

    Time frame: 8 weeks

  3. Changes in Insulin Sensitivity

    Insulin Sensitivity will be assessed using the homeostasis model assessment of insulin resistance (HOMA-IR), which is calculated from insulin and glucose concentration from a 12 hours fasting blood sample.

    Time frame: 8 weeks

  4. Changes in Fasting Lipids

    Changes in concentration of Apolipoprotein B and triglycerides will be measured from a 12 hours fasting blood sample.

    Time frame: 8 weeks

  5. Changes in Inflammatory Markers

    Changes in concentration of C-reactive protein and Interleukin-1beta will be measured.

    Time frame: 8 weeks

  6. Free triiodothyronine (fT3)

    Change in serum levels of fT3 will be measured.

    Time frame: 8 weeks

Other outcomes

  1. Correlation of longitudinally measured parameters

    Breath acetone measurements and continuous glucose monitoring will be conducted and correlated to the fat volume change.

    Time frame: 8 weeks

  2. Serum Metabolomics

    Metabolomics provides an insight into the organisms current metabolite profile. Exploring the effect of intermittent fasting on specific metabolites could provide important insights.

    Time frame: 8 weeks

  3. Genetic Analysis

    Genes associated with obesity could have an effect on the efficacy of the intermittent fasting intervention and genetic analysis may provide an important step towards personalized medicine.

    Time frame: 8 weeks

  4. LDL Particle Size

    Changes in serum LDL particle size might be measured.

    Time frame: 8 weeks

  5. Fecal Microbiome

    Sequencing will be used to identify the composition of bacteria and archaea within the fecal samples. Exploring the changes in the microbiome induced by intermittent fasting could provide valuable insights.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Endocrinology, Diabetology and Clinical Nutrition
    Zürich, 8091, Switzerland
    Recruiting
    • Philipp Gerber, MD · Contact
    • Nina Derron, PhD · Contact
    • Johanna Zehnder, MSc · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 259 non-industry interventional studies with no phase under Intermittent Fasting, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 24 months is above that.

Counting every sponsor, half of 265 studies reached it within 17 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 21, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Jan 2027
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06323889
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Sep 23, 2024
Primary completion
Sep 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 20, 2024

Study contacts

Leonie Mönch, MSc
Contact
leonie.moench@usz.ch
+41 44 255 31 64
Philipp Gerber, MD
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion